our thanks results our highlight key Q&A. on milestones, you, everyone and arrange and programs then remarks we it back to call. for my joining to discuss before financial will to David will to provide pass takeaways the the updates quarter platform move I for David the first I and Thank upcoming
the lost nerve each for memories that the cognitive that other. fix effective with treatment is so in treating are the call disease. loss As with other I Alzheimer's did cells synaptic both an also today's developing and are we we drug in XProXXXX, dysfunction CNS begin or pathologies. a it of where neurodegeneration cell the Alzheimer's of or data patients Nerve Alzheimer's both disease, neuroinflammation important and Cognitive when neuroinflammation decline memories role. hypothesis, which for Synapses with XProXXXX and loss are are where The nerve synaptic patients synaptic drug one be communicate. wires with occur combination Alzheimer's plays decline that Alzheimer's far, for indications last quarter, I believe Recapping can't on the our communicate released of results to as disease. Based death pathologies. cells will disease cells to or appears developing are We nerve in disease causes these nerve the known the die is dysfunction that must allow are with in cells can improve to neurodegeneration stored.
Our decline. dementia Alzheimer's treat Alzheimer's and that of must We controlled program core a controlling is pathology all to believe neuroinflammation neuroinflammation cognitive with is about be XProXXXX. targeting
an in with in the presented once injection. of On one kilogram per that matter data of inflammatory in novel demonstrate non-invasive and and to neuroinflammation presented sample the treatment need one benefits focus measure cell significantly XX-week patients both XXrd substantially of is decreased. with matter data -- to with with a suggests -- a disarray we a six Fluid. the had XPro. be improved The Alzheimer's of patient decreases We biomarkers that measures in Significant had is of on neurofilament correlation CSF suggesting white may highly measure from measures proteome XProXXXX I had provides in CSF quality significant in puncture. XPro example period of decrease group disease. January, of expanded that CSF water week the data of fiber remodeling and the improvements water spare effects highlights increase weekly as nerve demonstrated over matter between both in full lumbar cytokines the the quality. and Contactin-X patients XXXX function. invasive Highly caused CNS using completed significant the group impaired a to neuroinflammation We presented low-dose we controlling who treatment that of matter white high-dose months death into cortical insight of Neurogranin obtained white in on measurements, improvements synaptic a of four by three of patients and a Visinin-Like puncture and July We nine XPro an protein will provide Spinal density, reported in who for one gray a to XPro, subcutaneous free neurodegeneration MRI hints the measure lumbar will novel additional of CSF in proteins these presentation. synaptic free nine Cerebral milligram
the unique had measures period neuroinflammation progressive. result the Of work. with return in the scans After or gray quit in months six responded from his the not his improved showed matter his cognitive three-month during this therapy, work patient the to -- but improvements reported decrease was were patient those scan, the dementia he one and was XPro we white showed of only months. and of had had presented he or of retire patients to a their who three that patients because unique. note, January of performance in in quality greatest the was patient was This nine we stable greatest over able cognition Although, we Eight presentation. because to in
on study format you on review would website. these KOL our the deck extension are the that the treatment demonstrate starting neuroinflammation and from end to placebo-controlled presentation. on webinar continue with clearly our neuroinflammation. study. It compelling. is the intend In decrease the non-confidential opted committed in extension a that in in who what meantime, blinded by and in provide randomized have study their least XProXXXX generate corporate when January Phase trial found XPro a results Also with I They stay continue for follow find Alzheimer's I slide patients is on to I've the We injection as at updates the a on our three talked available all patients of disease to We to encourage who slide XX on our remain we data further in week about the We these to progress. of in a website. subcutaneous given a year. once months with the also available patients to
study allows therapy. reminder Phase the three an patients I months then duration additional the nine The As of can join a of study to is opt months. extension that an
on a study -- who really do the only in the pathology. X give of are all is future handful provide program. results design. extension additional neuroinflammation plays core in the We that? for diseases attribute and ability Phase year. XProXXXX, XPro report you're have of What that psychiatric I Needless who we receive we will Phase Alzheimer's control If additional long-term provide new our is you treat With disease. to-date, drug those developing patients the across data an therapy data role. trial on any from large summer, XPro can disease remarkable and treat have patients been neuroinflammation we amyloid, mean A patients a three-month about can from of say, details neurodegenerative this into who excited very data its biomarker study, a important a remain CNS X we neuroinflammation by insight based targets in When where where cuts the this of a to XProXXXX really of range to
and the Innovation a substantial. US, gives involves trial-and-error grant need through the resistant the advancements. depression cost that the The once for is with on A It from for paradigm field. depression Research million will estimated is year NIH increases over and depression. -- of and the much the operating exceeds that use therapeutic a billion system. that million length There a approach find the cost US of the works. a is XProXXXX supported therapies an A is two by is the is X to $X.X So cycling frustrating the us substantial. treatment Phase Business of for is health example from current hit-and-miss current suffer This treatment that estimated labeled seven care trial Small treatment-resistant patients for treatment-resistant bigger and we real the The cost money trial. is X patients administration $XX team that market treatment-resistant In associated clinical to receive regimens. to a Phase failed This one they TRD. treatment patient have care, is
resistance As treated believe routine to to to with neuroinflammation. response six more drug therapies. are depression biomarkers XPro likely development. more drugs of development provide biomarkers patients we for treatment confirmed, AD the is is use determine that the trial, weeks of confirm due will Once inflammation diagnosis to medicine in approach is use efficient psychiatric a effective not new of make and We will will therapy. The for precision enrolled
and connectivity per and measured will of through with XPro biomarkers two at Andy world's will study pioneers of versus baseline and of inflammation. a Associate Felger two in this of improved The placebo-controlled weeks. Professor by placebo double-blind the conduct is XX collaboration Biomarkers We inflammation endpoint be be both Miller The will primary Emory of in MRI functional arm. reduction field trial Jen the patients six-week trial measured University. in six
of measures -- patients most Secondary endpoints depression. with include measure is of in treatment-resistant clinical which the motivation, sensitive
to patients of to while study. of compromise storm patients death We the drug the cohorts. program later double the The enrollment days trial endpoint COVID-XX the care. are that cytokine the we randomized, of cohort targets mechanical year. patients equal the XXX plus plus placebo-controlled is is in hospitalized enroll to due in ventilation used other COVID-XX XX placebo respiratory our sized track two following a to is for One during primary need standard high-risk Quellor with or designed begin standard is is blind, in care, name in on Quellor this The this trial COVID-XX. treat
the is trial XXX The will renal us Board secondary enrolled. new give after platform. to priming transfer data or a ICU Safety ultimately, be go Data first of INKmune cell the a the disease. and in onset neurologic, cardiovascular, patients. decision go, the of This NK will evaluating no-go is our endpoints summer, include will Monitoring proceed thromboembolic patients If group given, the
They outcomes. cells NK crucial cancer a and target innate part of disease have know, and of residual ability play is the to you the increasingly active target that cause relapse. As particularly are disease, role cancer important both which system, the immune in
which role very the months In but ground or for fact, high-risk T screening cancer. trial have any patients Current is disease -- disease candidates because aggressive not of marrow High-risk include causes -- to decreases Approximately just not MDS. they transplantation, across allows target the which INKmune MDS off the the survival. and MDS treatments cells cause to for one-third of bone serious the but a trial many their in play chemotherapy cells, overtaken X old. patients stem or in ultimately is them little are with with blast, NK of high-risk Phase marrow elderly. or of or relapse residual blast of their been cell delays transplantation that and we treatment which They're stem AML. are and a of patients progression syndrome UK, get patients in to clearing is in disorder, are many be -- prevents cell patients has with to the this frustrating are hematopoietic strategies. progressed functionally COVID-related the of chemotherapy the And myelodysplastic cases these This of effective
The show NK can makes patient's the that escalation own own be patients open-label to a that this cells and that to kill NK study we cells, by in cells, is primes immunotherapy emphasize This their trial, strategy. NK dose INKmune. I delivering reprogrammed therapy So, the will enroll therapy tumor. In hope sense. a nine
INKmune have All tolerability blast. safety patients is of of excess these IV. will and with endpoint primary The administered MDS
using blast. endpoints Secondary of which the these percentage criteria really Overall that and and response. in number also change is measures and rate, response include duration of hematologic the WHO in patients the the
our a easily website. recently We up put the It's the the to short have Phase opportunity We attractive. X, a expand trial. results are moved video really five-minute on if into
does have way, cellular a patients INKmune wonderful To cells NK kill molecular why interactions to that own the with the to that another plenty of be to have them kill this cancer, -- cells cancer. activate say So prime. all to the patient knives they and And clear as really need And guns them cells. I and but INKmune to trigger. the job They cells NK patient's NK NK by after to those trigger failed cancer. to that need going tumors. explaining of missiles and put resistant provides most now, get like
said, I you it. our take on at found look and video hope the As can be a we website
once promising hope has pandemic delayed Finally, INBXX as to change we quarter to trial MUCX-positive better a and X cancer last is oncology program our initiate Phase controlled. there's indicated been We COVID-XX. no the been due in
been dormant tyrosine not clinically until the MUCX hope Similarly, we tumors to X Phase clarity We a floor has David completely programs the CFO in initiated laboratory financial on and pandemic back expressing our occur inhibitors and the the once NASH this will understood. turn is program discuss to the INBXX results this kinase controlled. pandemic better now research upcoming future announcements. to is combination have in trial with not have will of continue. the on I of these Although Moss, more
